Based on the paradigm that OV therapy generates potent antitumor T cell responses, VSV’s ability to increase CD8 T cell infiltration of the cold B16 melanoma tumor suggested that it may be an ideal candidate to be combined with immune checkpoint blockade (ICB) therapy. The gene discussed is CD8A; the disease is melanoma.